- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05921994
Estudio observacional, prospectivo y multicéntrico a largo plazo para recopilar en una población real datos sobre el patrón de tratamiento de secukinumAb en pacientes adultos con hidradenitis supurativa de moderada a grave. (ANIMA)
ESTUDIO OBSERVACIONAL, PROSPECTIVO, MULTICÉNTRICO A LARGO PLAZO PARA RECOPILAR EN UNA POBLACIÓN REAL DATOS SOBRE EL PATRÓN DE TRATAMIENTO DE SECUKINUMAB EN PACIENTES ADULTOS CON HIDRADENITIS SUPURATIVA (HS) DE MODERA A GRAVE (ANIMA)
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.
In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Aachen, Alemania, 52064
- Novartis Investigative Site
-
Ahaus, Alemania, 48683
- Novartis Investigative Site
-
Annaberg-Buchholz, Alemania, 09456
- Novartis Investigative Site
-
Bad Steben, Alemania, 95138
- Novartis Investigative Site
-
Baden-Baden, Alemania, 76530
- Novartis Investigative Site
-
Berlin, Alemania, 12159
- Novartis Investigative Site
-
Berlin, Alemania, 13595
- Novartis Investigative Site
-
Bielefeld, Alemania, 33647
- Novartis Investigative Site
-
Bochum, Alemania, 44791
- Novartis Investigative Site
-
Bonn, Alemania, 53105
- Novartis Investigative Site
-
Brandenburg, Alemania, 14776
- Novartis Investigative Site
-
Bremen, Alemania, 28359
- Novartis Investigative Site
-
Buxtehude, Alemania, 21614
- Novartis Investigative Site
-
Bückeburg, Alemania, 31675
- Novartis Investigative Site
-
Chemnitz, Alemania, 09117
- Novartis Investigative Site
-
Chemnitz, Alemania, 09113
- Novartis Investigative Site
-
Cologne, Alemania, 51065
- Novartis Investigative Site
-
Delitzsch, Alemania, 04509
- Novartis Investigative Site
-
Dessau, Alemania, 06847
- Novartis Investigative Site
-
Dorsten, Alemania, 46282
- Novartis Investigative Site
-
Dortmund, Alemania, 44137
- Novartis Investigative Site
-
Dresden, Alemania, 01309
- Novartis Investigative Site
-
Düren, Alemania, 52349
- Novartis Investigative Site
-
Emsdetten, Alemania, 48282
- Novartis Investigative Site
-
Erlangen, Alemania, 91054
- Novartis Investigative Site
-
Falkenberg, Alemania, 04895
- Novartis Investigative Site
-
Falkensee, Alemania, 14612
- Novartis Investigative Site
-
Freising, Alemania, 85354
- Novartis Investigative Site
-
Geilenkirchen, Alemania, 52511
- Novartis Investigative Site
-
Gera, Alemania, 07548
- Novartis Investigative Site
-
Gernsbach, Alemania, 76593
- Novartis Investigative Site
-
Gladbeck, Alemania, 45964
- Novartis Investigative Site
-
Großenhain, Alemania, 01558
- Novartis Investigative Site
-
Hamburg, Alemania, 20246
- Novartis Investigative Site
-
Hamburg, Alemania, 22143
- Novartis Investigative Site
-
Hanover, Alemania, 30159
- Novartis Investigative Site
-
Haslach im Kinzigtal, Alemania, 77716
- Novartis Investigative Site
-
Hofgeismar, Alemania, 34369
- Novartis Investigative Site
-
Jena, Alemania, 07743
- Novartis Investigative Site
-
Jülich, Alemania, 52428
- Novartis Investigative Site
-
Karlsruhe, Alemania, 76133
- Novartis Investigative Site
-
Kempen, Alemania, 47906
- Novartis Investigative Site
-
Lübeck, Alemania, 23538
- Novartis Investigative Site
-
Magdeburg, Alemania, 39120
- Novartis Investigative Site
-
Magdeburg, Alemania, 39104
- Novartis Investigative Site
-
Mainz, Alemania, 55116
- Novartis Investigative Site
-
Marburg, Alemania, 35043
- Novartis Investigative Site
-
Minden, Alemania, 32429
- Novartis Investigative Site
-
Mönchengladbach, Alemania, 41063
- Novartis Investigative Site
-
Neu Wulmstorf, Alemania, 21629
- Novartis Investigative Site
-
Nuremberg, Alemania, 90419
- Novartis Investigative Site
-
Oberasbach, Alemania, 90522
- Novartis Investigative Site
-
Oelde, Alemania, 59302
- Novartis Investigative Site
-
Peitz, Alemania, 03185
- Novartis Investigative Site
-
Potsdam, Alemania, 14469
- Novartis Investigative Site
-
Remscheid, Alemania, 42897
- Novartis Investigative Site
-
Selters, Alemania, 56242
- Novartis Investigative Site
-
Simmern, Alemania, 55469
- Novartis Investigative Site
-
Soest, Alemania, 59494
- Novartis Investigative Site
-
Stolberg, Alemania, 52222
- Novartis Investigative Site
-
Unna, Alemania, 59423
- Novartis Investigative Site
-
Wittlich, Alemania, 54316
- Novartis Investigative Site
-
Wuppertal, Alemania, 42103
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Alemania, 79068
- Novartis Investigative Site
-
Rheinstetten, Baden-Wurttemberg, Alemania, 76287
- Novartis Investigative Site
-
-
Bavaria
-
Haßfurt, Bavaria, Alemania, 97437
- Novartis Investigative Site
-
Kulmbach, Bavaria, Alemania, 95326
- Novartis Investigative Site
-
Lauf an der Pegnitz, Bavaria, Alemania, 91207
- Novartis Investigative Site
-
Nuremberg, Bavaria, Alemania, 90402
- Novartis Investigative Site
-
-
Brandenburg
-
Panketal, Brandenburg, Alemania, 16341
- Novartis Investigative Site
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Alemania, 22549
- Novartis Investigative Site
-
-
Lower Saxony
-
Lingen, Lower Saxony, Alemania, 49809
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Bergen auf Rügen, Mecklenburg-Vorpommern, Alemania, 18528
- Novartis Investigative Site
-
Kröpelin, Mecklenburg-Vorpommern, Alemania, 18236
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Krefeld, North Rhine-Westphalia, Alemania, 47798
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Alemania, 55128
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Alemania, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Alemania, 04207
- Novartis Investigative Site
-
Leipzig, Saxony, Alemania, 04289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Wittenberg, Saxony-Anhalt, Alemania, 06886
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
Descripción
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
- Patients who provide written informed consent to participate in the study
- Male and female patients with ≥18 years of age
- Diagnosis of clinically unequivocal moderate to severe HS
- Patients for whom a therapy with secukinumab is medically indicated
- Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
- Treatment with secukinumab according to the latest version of SmPC
- Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit
Exclusion Criteria:
Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:
- Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
- Previous exposure to IL-17 inhibitors
- For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
secukinumab
Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication. |
Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of patients receiving up-titration
Periodo de tiempo: Up to 24 months
|
Proportion of patients receiving up-titration (q4w-to-q2w) |
Up to 24 months
|
|
Proportion of patients receiving down-titration
Periodo de tiempo: Up to 24 months
|
Proportion of patients receiving down-titration (q2w-to-q4w) |
Up to 24 months
|
|
Time to up-titration and down-titration
Periodo de tiempo: Up to 2 years
|
Time to up-titration and down-titration |
Up to 2 years
|
|
Duration of q4w treatment with secukinumab after dose reduction
Periodo de tiempo: Up to 2 years
|
Duration of q4w treatment with secukinumab after dose reduction |
Up to 2 years
|
|
Proportion of patients who receive more than one up-and/or down titration
Periodo de tiempo: Up to 24 months
|
Proportion of patients who receive more than one up-and/or down titration |
Up to 24 months
|
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Periodo de tiempo: Up to 2 years
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab |
Up to 2 years
|
|
Number and type of surgical interventions
Periodo de tiempo: Up to 2 years
|
Number and type of surgical interventions
|
Up to 2 years
|
|
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Periodo de tiempo: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Periodo de tiempo: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Periodo de tiempo: Up to 24 months
|
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment. |
Up to 24 months
|
|
Mean reduction of Abscesses and inflammatory nodules (AN) count
Periodo de tiempo: Up to 24 months
|
Mean reduction of Abscesses and inflammatory nodules (AN) count |
Up to 24 months
|
|
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Periodo de tiempo: Up to 24 months
|
The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form. |
Up to 24 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones
- Enfermedades de la piel
- Infecciones bacterianas
- Infecciones bacterianas y micosis
- Enfermedades de las glándulas sudoríparas
- Enfermedades De La Piel Bacterianas
- Enfermedades De La Piel Infecciosas
- Supuración
- Hidradenitis
- Enfermedades de la piel y del tejido conectivo
- Hidradenitis supurativa
- secukinumab
Otros números de identificación del estudio
- CAIN457MDE01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .